Pharma BD Deal Intelligence
A conviction bet on an unproven modality: Celgene paid Forma $225M upfront for a 3.5-year option on its protein-homeostasis pipeline, framed by observers as 'an attractive call option,' though the payoff was explicitly years away.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Celgene doubles down on Forma with a $600M discovery deal tied to a buyout option, signaling deep conviction in protein homeostasis as a next-wave oncology…
Celgene expands its pact with Forma, recognizing protein-homeostasis chemistry as a strategic complement to its IMiD franchise.
Celgene's Rupert Vessey on extending the pact: 'Our continued collaboration with FORMA is based upon the quality of their drug candidates, their adaptability…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Celgene paid Forma $225M upfront for a 3.5-year option-to-license arrangement on Forma's protein-homeostasis oncology pipeline. The deal was strategically notable as one of the largest preclinical option deals of 2014 and presaged the broader degrader/molecular-glue wave.
Protein homeostasis is the cellular machinery (E3 ligases, chaperones, deubiquitinases, the ubiquitin-proteasome system) that controls protein stability. Dysregulation drives cancer and other diseases, and selectively degrading or stabilizing proteins offers a route to drug 'undruggable' targets across hematologic malignancies and solid tumors.
In 2014 protein homeostasis as a drug-discovery platform was nascent. Celgene already owned the foundational franchise — Revlimid (lenalidomide) and Pomalyst (pomalidomide) were later understood to act through cereblon-mediated protein degradation, generating combined revenue exceeding $5B annually. Competing platforms came from Arvinas (PROTACs, founded 2013), C4 Therapeutics (founded 2016), and Kymera Therapeutics (founded 2016), all leveraging targeted protein degradation. Forma's edge was a broad chemistry platform across E3 ligases, chaperones and deubiquitinases applicable to oncology and beyond. The 2014 deal was structured as a 3.5-year discovery alliance with Celgene retaining options for two additional terms ($375M aggregate) and an eventual buyout right. Celgene exercised the first extension option in August 2017 for an additional $195M upfront, validating the platform. The deal mattered because it presaged the molecular glue/degrader wave that became one of oncology's hottest modalities by 2020.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Forma Therapeutics Holdings Inc. (this deal) | 2014 | $600M | — |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
← Browse all deals · How we score deals
More: 2014 deals · Celgene Corporation deals · Hematology deals